Associated Papers
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
41053251 (PubMed )
Supplement: 41598_2025_18662_MOESM1_ESM.docx
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
38536921 (PubMed )
Supplement: sciadv.adm9859_sm.pdf
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.
Izumi M et al.
Scientific Reports, 2021
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F et al.
Cancer Medicine, 2019
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
30060526 (PubMed )
Supplement: cancers-10-00248-s001.docx
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
George J et al.
Nature Communications, 2018
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J et al.
Nature Communications, 2017
28548087 (PubMed )
Supplement: ncomms15503-s1.pdf
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
McGranahan N et al.
Science Translational Medicine, 2015
Somatic changes in primary liver cancer in Russia: a pilot study.
Kalinina O et al.
Mutation Research, 2013
Select a paper to view details